Tag - SRDX

Developments

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform. The...

November 5, 2025

Developments

FDA clears Surmodics’ Sublime dilatation catheter

Surmodics (NASDAQ:SRDX) received FDA 510(k) clearance for its Sublime radial access dilatation catheter. The company noted that at 250 cm, the Sublime catheter has the longest working length of currently available...

August 6, 2020

Developments

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

Surmodics (NASDAQ:SRDX) received FDA breakthrough device designation for its sirolimus-coated balloon (SCB), called Sundance, for the treatment of critical limb ischemia (CLI) and below-the-knee arterial disease. CLI...

October 29, 2019

Tag - SRDX

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

FDA clears Surmodics’ Sublime dilatation catheter

Surmodics gets FDA breakthrough device designation for sirolimus-coated balloon

Subscribe